Weatherly Asset Management L. P. lifted its holdings in shares of Merck & Company, Inc. (NYSE:MRK) by 0.6% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 7,426 shares of the company’s stock after buying an additional 42 shares during the period. Weatherly Asset Management L. P.’s holdings in Merck & were worth $476,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in MRK. Vigilant Capital Management LLC boosted its stake in shares of Merck & by 16.7% during the first quarter. Vigilant Capital Management LLC now owns 1,746 shares of the company’s stock worth $111,000 after buying an additional 250 shares during the period. Cascade Investment Advisors Inc. boosted its stake in shares of Merck & by 15.5% during the second quarter. Cascade Investment Advisors Inc. now owns 1,727 shares of the company’s stock worth $111,000 after buying an additional 232 shares during the period. Harbour Capital Advisors LLC acquired a new stake in shares of Merck & during the first quarter worth about $127,000. Mascoma Wealth Management LLC boosted its stake in shares of Merck & by 8.2% during the second quarter. Mascoma Wealth Management LLC now owns 2,474 shares of the company’s stock worth $159,000 after buying an additional 187 shares during the period. Finally, Gradient Investments LLC boosted its stake in shares of Merck & by 17.5% during the second quarter. Gradient Investments LLC now owns 2,710 shares of the company’s stock worth $174,000 after buying an additional 404 shares during the period. Institutional investors and hedge funds own 72.91% of the company’s stock.
Merck & Company, Inc. (NYSE MRK) opened at 63.78 on Thursday. Merck & Company, Inc. has a one year low of $58.29 and a one year high of $66.80. The stock has a market capitalization of $173.95 billion, a PE ratio of 34.53 and a beta of 0.80. The firm has a 50-day moving average of $64.46 and a 200-day moving average of $63.70.
Merck & (NYSE:MRK) last issued its quarterly earnings results on Friday, July 28th. The company reported $1.01 earnings per share for the quarter, topping analysts’ consensus estimates of $0.87 by $0.14. The company had revenue of $9.93 billion during the quarter, compared to analyst estimates of $9.75 billion. Merck & had a net margin of 17.14% and a return on equity of 26.02%. The business’s revenue for the quarter was up .9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.93 EPS. On average, equities research analysts forecast that Merck & Company, Inc. will post $3.87 earnings per share for the current year.
The business also recently declared a quarterly dividend, which was paid on Friday, October 6th. Stockholders of record on Friday, September 15th were paid a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 2.95%. The ex-dividend date of this dividend was Thursday, September 14th. Merck &’s dividend payout ratio is currently 76.11%.
TRADEMARK VIOLATION WARNING: This piece of content was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://sportsperspectives.com/2017/10/12/weatherly-asset-management-l-p-acquires-42-shares-of-merck-company-inc-mrk.html.
Several equities research analysts have recently weighed in on the stock. BMO Capital Markets reiterated an “outperform” rating and set a $73.00 target price (down previously from $74.00) on shares of Merck & in a research note on Monday, July 24th. BidaskClub downgraded shares of Merck & from a “sell” rating to a “strong sell” rating in a research report on Wednesday, July 19th. Zacks Investment Research downgraded shares of Merck & from a “hold” rating to a “sell” rating in a research report on Wednesday. Citigroup Inc. set a $65.00 price objective on shares of Merck & and gave the company a “hold” rating in a research report on Wednesday, July 5th. Finally, Credit Suisse Group restated an “outperform” rating and issued a $74.00 price objective (down previously from $75.00) on shares of Merck & in a research report on Tuesday, September 5th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $69.69.
About Merck &
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.